Please assess the completion status of the following clinical trial:

Trial Title: ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \> 40 years;~* Women of childbearing potential must use two reliable contraceptive methods during the entire trial, from day 1 to one month after the end of the trial.~* Signing the study consent form;~* Stable cART since at least 3 months (ie no recent drug change);~* HIV-RNA below 100 copies for at least 6 months;~* HDL-cholesterol \<1.29 mmol/l for men; \<1.42 mmol/l for women~Exclusion Criteria:~* Pregnancy or lactation;~* Congestive Heart Failure;~* Malignant Hypertension;~* Acute or chronic coronary artery diseases;~* Any known cardiac arrhythmias;~* Diabetes;~* Concomitant cancer, rheumatologic disease or inflammatory bowel diseases;~* Concomitant renal or hepatic disease:~  * Creatinine above 150 micromol/L~ * Transaminases above 5 times upper normal limit~ * Prothrombin time (Quick) value below 50%;~* Prior intolerance to niacin therapy (reported in a medical report);~* Cyclosporine, anti-inflammatory drugs (other than aspirin) or cytokine therapy in concomitant intake;~* Abnormal thyroid function;~* Excessive consumption of alcohol;~* Known severe lactose intolerance.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ER Niacin/laropipant (Type: ACTIVE_COMPARATOR): ER niacin/laropiprant 1g/20 mg for the first 4 weeks and 2g/40mg from week 5 to the end of the study.
- ER Niacin/laropipant Placebo (Type: PLACEBO_COMPARATOR): ER niacin/laropiprant placebo p.m.

Based on this trial design, predict the completion outcome and termination type (if applicable).